News

Diagnosing sepsis is a longstanding challenge in medicine because the clinical signs and symptoms are nonspecific and, in the absence of a gold standard for identifying patients with the disease, the focus has remained largely on identifying the culprit pathogen, says Chaz Langelier, M.D., Ph.D., associate professor of medicine in the division of infectious diseases at the University of California, San Francisco (UCSF), and a Chan Zuckerberg Biohub investigator. But an assay developed by UCSF researchers that deploys metagenomic next-generation sequencing (mNGS) of both pathogens and host immune response could be a real gamechanger. Diagnosing sepsis is a longstanding challenge in medicine because the clinical signs and symptoms are nonspecific and, in the absence of a gold standard for identifying patients with the disease, the focus has remained largely on identifying the culprit pathogen, says Chaz Langelier, M.D., Ph.D., associate professor of medicine in the division of infectious diseases at the University of California, San Francisco (UCSF), and a Chan Zuckerberg Biohub investigator. But an assay developed by UCSF researchers that deploys metagenomic next-generation sequencing (mNGS) of both pathogens and host immune response could be a real gamechanger.